SAN DIEGO–(BUSINESS WIRE)–Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ …
Tag Archives: ignyta
December, 2017
May, 2017
-
15 May
FDA Grants Breakthrough Therapy Designation to Ignyta’s Cancer Drug Entrectinib
SAN DIEGO–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation (BTD) to entrectinib “for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric …
March, 2015
-
19 March
Ignyta Advances its Precision Oncology Vision with its Acquisition of Four Targeted Cancer Programs from Teva
Precision oncology biotech Ignyta has acquired worldwide rights and assets relating to four targeted oncology development programs from Teva Pharmaceutical Industries. The companies announced that Ignyta will acquire four oncology assets from Teva in exchange for 1.5 million shares, or six percent of Ignyta’s common stock. Concurrently, Ignyta has entered …
February, 2015
-
5 February
Ignyta’s Lung Cancer Drug Receives Orphan Drug Status from the FDA
Today, precision oncology biotechnology company Ignyta, Inc. announced that its lead candidate has been granted orphan drug designation from US health regulators. According to the company, the US Food and Drug Administration (FDA) granted Ignyta’s entrectinib orphan drug designation for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive and ALK-positive non-small …